Moderna rose more than 17% at one point during Wednesday’s session before closing up 16.07%. The immediate catalyst was the company’s announcement of a global settlement with Arbutus Biopharma and Genevant Sciences over long-running patent litigation. Moderna agreed to pay up to $2.25 billion to resolve the dispute, including a $950 million upfront payment and potential additional payments. The expense will be recorded in the first quarter, with year-end cash and cash equivalents projected at $4.5 billion to $5.0 billion.

However, the headline benefit goes beyond the settlement itself. What truly excited the market was the implication: the patent overhang is finally clearing, allowing Moderna to redirect management focus, capital allocation, and research resources toward its next growth engine — “AI + healthcare.”

What Happened: “AI + Healthcare”

The settlement covers litigation related to Moderna’s Spikevax and mRESVIA vaccines and provides future clarity for its broader infectious disease portfolio, including pipeline candidates. Investors viewed the settlement amount as “better than feared,” as prior concerns had centered around potential liabilities approaching $5 billion, which could have raised liquidity concerns. That said, tail risks remain. Moderna continues to appeal to the U.S. Court of Appeals for the Federal Circuit, arguing that its “government contractor immunity” defense under federal law should limit its liability.

In the market’s eyes, however, these legal issues are now secondary. The larger narrative is that Moderna is systematically embedding AI into its research and operations. The company is reportedly working closely with OpenAI to advance mRNA drug development, using AI in trial design, data analysis, predictive modeling, production network optimization, regulatory documentation, and internal process efficiency.

From a technological standpoint, the pairing makes sense. The mRNA platform is inherently data-driven, programmable, and process-optimizable — precisely the kind of structured system where AI excels. Moderna describes its R&D engine as a combination of proprietary digital drug design tools and highly automated manufacturing facilities. Personalized cancer vaccine programs, in particular, rely heavily on DNA and mRNA sequencing data and algorithmic identification of tumor neoantigens.

Nvidia CEO Jensen Huang has long endorsed this trajectory, frequently describing AI-driven healthcare and biology as “the next extraordinary revolution” in global technology. He has even suggested that the era when everyone needed to learn computing is fading, and that biology and medicine represent the future frontier. Investors appear willing to embrace that vision.

Outlook: Compelling Story, Difficult Execution

Entering 2026, partnerships in AI-driven drug discovery have accelerated significantly. On January 5, Insilico Medicine announced a multi-year research collaboration with French pharmaceutical company Servier, worth up to $888 million, targeting challenging oncology assets. Insilico, which listed in Hong Kong at the end of 2025, raised approximately HK$2.277 billion in its IPO — the largest biotech IPO of the year — and saw its share price rise more than 90% by February 2026.

Yet skepticism persists within the AI drug discovery sector. The core challenge remains data. AI model performance depends heavily on high-quality training data, and this constraint has not been fully resolved.

A senior R&D executive at a leading domestic pharmaceutical company commented that while improving success rates is the ideal outcome, it remains to be validated over time. Currently, the primary objective of applying AI in drug development is cost and efficiency optimization — reducing the traditional ten-year, multi-billion-dollar development cycle to roughly five years at a fraction of the cost.

A founder of a CRO firm noted that most AI models rely on publicly available or internal company data. Medical data sharing rates remain below 20%, and inconsistent data standards across sources create “data silos,” severely limiting model generalization capabilities.

Returning to Moderna, the company does possess structural advantages. It is not merely “adding AI to biotech” — it operates a highly standardized, data-intensive, programmable mRNA platform. However, if over the next one to three years it fails to consistently validate the “AI + healthcare” model through tangible clinical progress — whether in personalized cancer vaccines or broader mRNA therapies — the AI narrative may remain a supportive factor rather than a core bull-market catalyst.

In the short term, the patent settlement eliminates a significant uncertainty. While the large payment will impact first-quarter earnings, it removes future royalty obligations. If Moderna prevails in its appeal, it may even recover part of the settlement, which would be positive for cash flow and long-term profitability.

In the medium term, investors will focus on two key areas: first, whether collaboration with OpenAI yields measurable efficiency gains in preclinical research, trial design, and regulatory filings; second, whether AI-driven projects such as personalized cancer vaccines can deliver compelling clinical data.

Longer term, commercialization will be decisive. Demis Hassabis, head of Google DeepMind and recipient of the 2024 Nobel Prize in Chemistry, recently outlined a bold vision at Davos: AI-designed drugs entering clinical trials within a year and ushering in a “golden era of drug discovery” over the next decade or more. However, this vision depends on AI-designed drugs successfully completing Phase III trials, gaining regulatory approval, and achieving commercial success.

To date, no AI-developed drug has completed Phase III trials and reached full commercialization globally. This is why industry leaders caution that it is still too early to discuss definitive improvements in success rates.